Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP's stock price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $8.05 and traded as low as $7.45. Aurinia Pharmaceuticals shares last traded at $7.59, with a volume of 1,404,253 shares traded.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.
View Our Latest Analysis on AUPH
Aurinia Pharmaceuticals Trading Down 1.5%
The company has a quick ratio of 5.26, a current ratio of 5.93 and a debt-to-equity ratio of 0.16. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 31.43 and a beta of 1.16. The business has a 50 day moving average price of $8.07 and a 200-day moving average price of $8.07.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. The firm had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. As a group, research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Tang Capital Management LLC grew its stake in Aurinia Pharmaceuticals by 16.6% during the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after purchasing an additional 1,200,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Aurinia Pharmaceuticals by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock worth $15,535,000 after buying an additional 112,113 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in Aurinia Pharmaceuticals by 10.2% during the 4th quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company's stock worth $13,401,000 after buying an additional 138,054 shares during the last quarter. Nuveen LLC bought a new position in Aurinia Pharmaceuticals during the 1st quarter worth approximately $10,014,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in Aurinia Pharmaceuticals during the 4th quarter worth approximately $9,662,000. Institutional investors and hedge funds own 36.83% of the company's stock.
Aurinia Pharmaceuticals Company Profile
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
